We are raising funds!
Funds for a promising research project that has great potential to help millions of people suffering from Age-Related Macular Degeneration (AMD), the most common cause of blindness in seniors world wide. There is no cure or effective treatment for AMD.
Our pilot study will examine the effectiveness of bioenergy in self-care for this condition. Two patients have already experienced great benefits using this approach. The amazing results -- visible in retinal scans -- are the impetus for the study.
It will be led by two highly accomplished professionals: Garret Yount, PhD, a renowned research scientist; and Irene A. Barbazetto, MD, an internationally recognized specialist in AMD.
We need to raise $50,000 for the initial phase of this study. Please help us reach this critical goal by donating today. Your contribution may help us find a self-care approach that could benefit millions!
More details below
Dear Friend,
My name is Michael Mannion. Trish Corbett and I founded The Mindshift Institute (501c3) in 1999. We have produced scores of evening talks and 12 annual conferences focused on new knowledge that expands our worldview. Our latest effort is something new for us—a clinical pilot study of a bioenergy self-healing method.
We are writing to ask you to consider making a fully tax-deductible donation to support an exciting and promising research project that has great potential to help millions of people suffering from Age-Related Macular Degeneration (AMD), the most common cause of blindness in seniors worldwide for which there is no effective treatment.
Our pilot study will examine the effectiveness of bioenergy in self-care for this condition. Two patients have already experienced healing using this approach. Their amazing results are the impetus for the study. It will be led by two highly accomplished professionals: Garret Yount, PhD, a renowned research scientist; and Irene A. Barbazetto, MD, an internationally recognized specialist in AMD.
We need to raise $50,000 for the initial phase of the study. Will you help us reach that goal?
We guarantee that 100% of your donation will go to the pilot study. There is no overhead involved with your donation to The Mindshift Institute (501c3). Your donation is analogous to a high-leverage financial investment in which a relatively small amount of money can result in an extremely large benefit.
If it would help you in making your decision to donate to this study, Dr Yount is willing to have a brief conversation with you to address questions you may have.
You can make out a check to The Mindshift Institute and mail it to us at 3 West 87th Street, Apt 1D New York NY 10024 or make your donation via Pay Pal using the “Donate” link above or at the bottom of the home page at www.MindshiftInstitute.org
We hope you give this request serious thought and look forward to your response. Any donation to The Mindshift Institute (a 501c3 nonprofit) to help make this pilot study a reality will be greatly appreciated and could help millions.
Learn more about the successful use of bioenergy self-care with AMD, including irrefutable retinal scans, read the article at this link:
https://www.merliannews.com/for-patients-only-bioenergy-self-care-for-a-serious-eye-disease
All our best,
Trish and Michael
The Mindshift Institute
MORE ABOUT OUR PILOT STUDY OF SELF-HEALING WITH BIOENERGY
Trish has experienced a complete remission of the fatty deposits called drusen which determine the extent of loss of vision with intermediate dry macular degeneration (AMD). She has accomplished this through the use of orgone energy.
In addition to the resorption of the drusen associated with her AMD, Trish has experienced improvement in her visual acuity from 20/60 and 20/40 to 20/35 and 20/30; as well as other improvements in eye health. Her use of orgone energy is responsible for this as well.
Every physician who has seen her before-and-after retinal scans has used one word to describe what they were observing—Amazing.
Trish and I went to California in early October 2024 and met with Dr Yount to discuss her use of bioenergy for her macular degeneration to see if he would like to conduct a study to determine if what she is doing might be of help to others with her condition. He was very interested and wants to undertake a pilot study. He has over 80 published papers in peer-reviewed journals and is one of only a few scientists to receive an NIH R01 top-tier grant to study the human bioenergy field.
Dr Yount understands that orgone energy has already shown a positive healing impact on Trish. He is an independent, open-minded scientist who knows that orgone energy is a real phenomenon. Our challenge is to discover how effective it can be with this condition.
After managing Trish’s care since April 2021, Dr Barbazetto has joined the pilot study. She will collect data on the of the use of orgone energy for self-care for intermediate dry macular degeneration, an eye disease that affects about 20 million Americans and hundreds of millions of people worldwide.
Dr Barbazetto will use her decades of experience as an expert clinician treating patients with AMD, along with her expertise as an investigator on national and international medical trials, to evaluate the clinical data being collected during the pilot study.
In its first phase, our project will enroll 20 people with AMD in a study using an orgone energy device for 12 months. In a second phase, there will be a blind study with two groups: half of the participants will use an orgone energy funnel and half will use a look-a-like placebo device.
We are inspired to undertake this project because of Trish’s positive results. Also, another patient with AMD in Dr Barbazetto’s care has been using an orgone device for many months and his drusen are gone as well as evident in his retinal scans. We believe that positive results with this study may lead to a larger clinical trial and open the door to other clinical trials of orgone energy in healing; a door that has been shut tight for decades.
Trish and I believe so strongly in the great potential of this effort that we are donating a substantial sum to help fund this crucial project. We are not people of means and this amount is significant for us. At ages 75 and 85, on fixed incomes, we need to be careful to provide for ourselves over the years to come. But we are willing to donate this amount because of the great benefit that may come from this study.
Would you consider making a significant donation to fund this Pilot Study so that we can begin in earnest in October 2025? We know this is a lot to ask, but we are not asking for something that we are not doing ourselves.
Again, you can make out a check to The Mindshift Institute and mail it to us at 3 West 87th Street, Apt 1D New York NY 10024 or using the donate button above.
ABOUT GARRET YOUNT
Garret Yount, PhD, is a Scientist at the Institute of Noetic Sciences (IONS) where his research focuses on mapping the mind-gene interface. In 1997, Dr. Yount was among the first scientists to be awarded a Research Project Grant (R01) from the National Institutes of Health to study qigong and other healing modalities involving the human biofield.
He obtained his BS from the Department of Molecular & Cell Biology at the Pennsylvania State University, and his PhD from the Department of Neurobiology & Behavior at the State University of New York at Stony Brook. He was then awarded two Postdoctoral Scholarships, one in the Langley Porter Psychiatric Institute at the University of California, San Francisco (UCSF), and the second in UCSF’s Brain Tumor Research Center. During his postdoctoral training at UCSF, he was awarded a Fellowship from the Robert Steel Foundation for Pediatric Cancer Research in New York.
Dr. Yount has a long-standing interest in developing methods and technologies for bridging molecular neurobiology with aspects of consciousness and extended human capacities. His doctoral thesis work in Stony Brook focused on deciphering molecular links between brain activity and the regulation of neuropeptide gene expression.
ABOUT IRENE A BARBAZETTO, MD
Irene A Barbazetto, MD is an internationally recognized expert in the treatment of macular degeneration, retinal vascular disease, retinal vein occlusion, hereditary retinal disease, and diabetes. The author of more than 40 peer-reviewed articles and book chapters, she serves on the Editorial Board of the prestigious journal Graefe’s Archive of Clinical and Experimental Ophthalmology. Dr. Barbazetto is the recipient of the 2009 Achievement Award from the American Academy of Ophthalmology. Her patients voted her as one of the best retina doctors, America’s “Most Compassionate Physicians,” and she received the “Patient’s Choice Award” in 2010. Her academic affiliations include Columbia University, NYU, and Manhattan Eye and Ear Hospital.
A graduate of Hamburg University, Germany, Dr. Barbazetto’s doctoral thesis investigated a newly developed vision-screening test (H-Test) for pre-school children and was awarded cum laude. She completed her ophthalmology residency in Lübeck, Germany, where she participated in the development of photodynamic therapy for the treatment of macular degeneration.
In addition to her clinical work, Dr. Barbazetto serves as an investigator on several national and international medical trials. She is a pioneer in the use of photodynamic therapy in the treatment of choroidal hemangioma and other ocular tumors and an active reviewer for several ophthalmologic publications. Dr. Barbazetto is a member of The American Society of Retina Specialists (ASRS), Association for Research in Vision and Ophthalmology (ARVO), European Vision and Eye Research (EVER), New York State Ophthalmologic Society (NYOS), and The American Academy of Ophthalmology (AAO).
  |
